Early use of asciminib for new CML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with CML in the last 3 months.
- You must have the specific BCR::ABL1 gene mutation (e13a2 or e14a2).
- You must have taken TKI therapy for 30 days or less, but other treatments like hydroxyurea are allowed.
- You must be generally active and able to care for yourself (ECOG score 0-2).
- Your liver, kidneys, and pancreas must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This study follows real-world patients who are taking a medicine called asciminib for chronic myeloid leukemia (a blood cancer) after their first treatment didn't work or stopped working. Researchers want to see how well asciminib actually helps patients in everyday practice.
This study looks at the safety and effects of the drug asciminib in young adults (18 and older) with a type of leukemia called chronic myeloid leukemia (CML). It uses information already collected from patients' medical records to see how well the drug works and how safe it is.
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
Hear when a new CML, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.